Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Dec;30(6):861–869. doi: 10.1111/j.1365-2125.1990.tb05452.x

Leukotrienes in the sputum and urine of cystic fibrosis children.

A P Sampson 1, D A Spencer 1, C P Green 1, P J Piper 1, J F Price 1
PMCID: PMC1368307  PMID: 1963072

Abstract

1. Leukotrienes (LTs) are potent pro-inflammatory mediators with actions relevant to the pathophysiology of cystic fibrosis (CF), including increased mucus production, bronchoconstriction, leucocyte chemotaxis, and increased vascular permeability. We have therefore investigated the potential role of LTs in children with CF. Leukotriene E4 levels were assessed in the urine of 30 normal (N) children (aged 1.3-12.7 years) and 30 CF children (1.6-14.3 years). Sputum from 13 of the CF children was analysed from LTB4, LTC4, LTD4, and LTE4. LTs were separated by reversed-phase h.p.l.c. and quantitated by radioimmunoassay. 2. Urinary LTE4 levels were log normally distributed, with geometric mean values (95% confidence intervals) of N: 88.4 (71.3-111) pmol mmol-1 creatinine (n = 30), and CF: 112 (70.6-177) pmol mmol-1 creatinine (n = 30; P greater than 0.05). Of the CF subjects, 33% had urinary LTE4 levels above 200 pmol mmol-1 creatinine, compared with 3.3% of the N children. 3. In sputum, mean (+/- s.e. mean) LT concentrations were (pmol g-1), LTB4: 44.3 +/- 10.8, LTC4: 4.9 +/- 1.3, LTD4: 1.8 +/- 0.9, and LTE4: 67.7 +/- 18.9 (n = 13). 4. Urinary LTE4 levels correlated significantly with sputum LTE4 levels (r = 0.673, P = 0.012), and with sputum levels of total cysteinyl-LTs (r = 0.660, P = 0.014). 5. In conclusion, total cysteinyl-LT content in sputum is 10-fold higher than previously reported, consisting primarily (91%) of LTE4. The high levels of LTE4 and LTB4 in sputum suggest involvement of LTs in the pathophysiology of CF. Urinary LTE4 levels may prove useful as a marker for cysteinyl-LT production in sputum.

Full text

PDF
863

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aharony D., Dobson P. T., Krell R. D. In vitro metabolism of [3H]-peptide leukotrienes in human and ferret lung: a comparison with the guinea pig. Biochem Biophys Res Commun. 1985 Sep 16;131(2):892–898. doi: 10.1016/0006-291x(85)91323-3. [DOI] [PubMed] [Google Scholar]
  2. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beyer G., Meese C. O., Klotz U. Stability of leukotrienes C4 and D4 in human urine. Prostaglandins Leukot Med. 1987 Oct;29(2-3):229–235. doi: 10.1016/0262-1746(87)90012-6. [DOI] [PubMed] [Google Scholar]
  4. Camp R., Jones R. R., Brain S., Woollard P., Greaves M. Production of intraepidermal microabscesses by topical application of leukotriene B4. J Invest Dermatol. 1984 Feb;82(2):202–204. doi: 10.1111/1523-1747.ep12259945. [DOI] [PubMed] [Google Scholar]
  5. Carlstedt-Duke J., Brönnegård M., Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9202–9206. doi: 10.1073/pnas.83.23.9202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Coles S. J., Neill K. H., Reid L. M., Austen K. F., Nii Y., Corey E. J., Lewis R. A. Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins. 1983 Feb;25(2):155–170. doi: 10.1016/0090-6980(83)90101-6. [DOI] [PubMed] [Google Scholar]
  7. Cromwell O., Walport M. J., Morris H. R., Taylor G. W., Hodson M. E., Batten J., Kay A. B. Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet. 1981 Jul 25;2(8239):164–165. doi: 10.1016/s0140-6736(81)90353-6. [DOI] [PubMed] [Google Scholar]
  8. Czarnetzki B. M., Rosenbach T. Chemotaxis of human neutrophils and eosinophils towards leukotriene B4 and its 20-w-oxidation products in vitro. Prostaglandins. 1986 May;31(5):851–858. doi: 10.1016/0090-6980(86)90018-3. [DOI] [PubMed] [Google Scholar]
  9. Feinmark S. J., Lindgren J. A., Claesson H. E., Malmsten C., Samuelsson B. Stimulation of human leukocyte degranulation by leukotriene B4 and its omega-oxidized metabolites. FEBS Lett. 1981 Dec 21;136(1):141–144. doi: 10.1016/0014-5793(81)81233-1. [DOI] [PubMed] [Google Scholar]
  10. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  11. Gilljam H., Strandvik B., Ellin A., Wiman L. G. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest. 1986 Oct;46(6):511–518. doi: 10.3109/00365518609083706. [DOI] [PubMed] [Google Scholar]
  12. Hall W. J., Hall C. B., Speers D. M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med. 1978 Feb;88(2):203–205. doi: 10.7326/0003-4819-88-2-203. [DOI] [PubMed] [Google Scholar]
  13. Heavey D. J., Soberman R. J., Lewis R. A., Spur B., Austen K. F. Critical considerations in the development of an assay for sulfidopeptide leukotrienes in plasma. Prostaglandins. 1987 May;33(5):693–708. doi: 10.1016/0090-6980(87)90035-9. [DOI] [PubMed] [Google Scholar]
  14. Keppler D., Huber M., Hagmann W., Ball H. A., Guhlmann A., Kästner S. Metabolism and analysis of endogenous cysteinyl leukotrienes. Ann N Y Acad Sci. 1988;524:68–74. doi: 10.1111/j.1749-6632.1988.tb38531.x. [DOI] [PubMed] [Google Scholar]
  15. Lee C. W., Lewis R. A., Tauber A. I., Mehrotra M., Corey E. J., Austen K. F. The myeloperoxidase-dependent metabolism of leukotrienes C4, D4, and E4 to 6-trans-leukotriene B4 diastereoisomers and the subclass-specific S-diastereoisomeric sulfoxides. J Biol Chem. 1983 Dec 25;258(24):15004–15010. [PubMed] [Google Scholar]
  16. Maltby N. H., Taylor G. W., Ritter J. M., Moore K., Fuller R. W., Dollery C. T. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):3–9. doi: 10.1016/0091-6749(90)90214-o. [DOI] [PubMed] [Google Scholar]
  17. O'Driscoll B. R., Cromwell O., Kay A. B. Sputum leukotrienes in obstructive airways diseases. Clin Exp Immunol. 1984 Feb;55(2):397–404. [PMC free article] [PubMed] [Google Scholar]
  18. Osborne D. J., Peters B. J., Meade C. J. The separation of leukotrienes and hydroxyeicosatetraenoic acid metabolites of arachidonic acid by high performance liquid chromatography (HPLC). Prostaglandins. 1983 Nov;26(5):817–832. doi: 10.1016/0090-6980(83)90065-5. [DOI] [PubMed] [Google Scholar]
  19. Rokach J., Hayes E. C., Girard Y., Lombardo D. L., Maycock A. L., Rosenthal A. S., Young R. N., Zamboni R., Zweerink H. J. The development of sensitive and specific radioimmunoassays for leukotrienes. Prostaglandins Leukot Med. 1984 Jan;13(1):21–25. doi: 10.1016/0262-1746(84)90098-2. [DOI] [PubMed] [Google Scholar]
  20. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  21. Verhagen J., Bel E. H., Kijne G. M., Sterk P. J., Bruynzeel P. L., Veldink G. A., Vliegenthart J. F. The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals. Biochem Biophys Res Commun. 1987 Oct 29;148(2):864–868. doi: 10.1016/0006-291x(87)90955-7. [DOI] [PubMed] [Google Scholar]
  22. Woodward D. F., Weichman B. M., Gill C. A., Wasserman M. A. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins. 1983 Jan;25(1):131–142. doi: 10.1016/0090-6980(83)90142-9. [DOI] [PubMed] [Google Scholar]
  23. Zakrzewski J. T., Barnes N. C., Costello J. F., Piper P. J. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987 Sep;136(3):779–782. doi: 10.1164/ajrccm/136.3.779. [DOI] [PubMed] [Google Scholar]
  24. Zakrzewski J. T., Sampson A. P., Evans J. M., Barnes N. C., Piper P. J., Costello J. F. The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects. Prostaglandins. 1989 Apr;37(4):425–444. doi: 10.1016/0090-6980(89)90093-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES